Art Krieg, Checkmate CSO

IPO bound? Five years in, Art Krieg and the Check­mate crew col­lect $85M to back up their 1-drug pipeline

Five years af­ter Art Krieg picked up a drug to make a bid in the fever­ish im­muno-on­col­o­gy space with a start­up called Check­mate Phar­ma­ceu­ti­cals, he and the team are still locked in to their sin­gle path­way ap­proach. And they just scored $85 mil­lion and a cou­ple of new mar­quee in­vest­ments to make some im­por­tant mid-stage moves on the R&D board.

The drug is CMP-001, which con­tains a CpG-A oligonu­cleotide that ac­ti­vates the TLR9 path­way to kick up an in­nate im­mune re­sponse to can­cer — one of the most pop­u­lar re­search strate­gies in the on­col­o­gy hand­book these days. And Check­mate says they are still the on­ly play­er in biotech to go af­ter this par­tic­u­lar path­way.

That’s not nec­es­sar­i­ly a val­i­da­tion of the ap­proach. Hot can­cer tar­gets like TIG­IT at­tract swarms of com­peti­tors, but it would leave Check­mate well ahead of any ri­val that might ap­pear.

Krieg, an oli­go ex­pert who moved from CEO to the CSO spot as the biotech moved in­to the clin­ic, has pas­sion­ate­ly be­lieved the ther­a­py can be dou­bled up with a PD-1 to amp up the im­pact for can­cer pa­tients. And they tied up with Keytru­da and Op­di­vo, the gold stan­dard in PD-1 check­points, to prove the point.

The goal here is to make a pipeline out of a prod­uct.

A key cat­a­lyst for the pri­vate play­er ar­rived last fall at SITC, when the biotech post­ed da­ta in­di­cat­ing a 25% over­all re­sponse rate for their Keytru­da-com­bo melanoma pa­tients who had al­ready proven to be re­sis­tant to an­ti-PD-(L)1 drugs. And that ev­i­dent­ly in­spired Lon­gi­tude Cap­i­tal and No­vo Hold­ings to lead the new round — al­most dou­bling the amount raised so far.

Oth­er new in­vestors in­clude Medix­ci (which puts a high pre­mi­um on fo­cus), Omega Funds, Clough Cap­i­tal Part­ners, Sec­toral As­set Man­age­ment and Bright­Edge, the ven­ture in­vest­ment fund of the Amer­i­can Can­cer So­ci­ety. Check­mate’s ex­ist­ing in­vestors Sofinno­va In­vest­ments, ven­Bio Part­ners, F-Prime Cap­i­tal and Decheng Cap­i­tal al­so stepped in.

These days, that kind of raise for a biotech in the clin­ic begs the ques­tion of whether Check­mate plans to pitch an IPO soon.

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

Abortion-rights protesters regroup and protest following Supreme Court's decision to overturn Roe v. Wade. (AP Photo/Gemunu Amarasinghe)

Fol­low­ing SCO­TUS de­ci­sion to over­turn abor­tion pro­tec­tions, AG Gar­land says states can't ban the abor­tion pill

Following the Supreme Court’s historic decision on Friday to overturn Americans’ constitutional right to an abortion after almost 50 years, Attorney General Merrick Garland sought to somewhat reassure women that states will not be able to ban the prescription drug sometimes used for abortions.

Following the decision, the New England Journal of Medicine also published an editorial strongly condemning the reversal, saying it “serves American families poorly, putting their health, safety, finances, and futures at risk.”

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Yong Dai, Frontera Therapeutics CEO

Scoop: Lit­tle-known Or­biMed-backed biotech clos­es $160M round to start gene ther­a­py tri­al

Frontera Therapeutics, a China and US biotech, has closed a $160 million Series B and received regulatory clearance to test its first gene therapy stateside, Endpoints News has learned.

Led by the largest shareholder, OrbiMed, the biotech has secured $195 million total since its September 2019 founding, according to an email reviewed by Endpoints. The lead AAV gene therapy program is for an undisclosed rare eye disease, according to the source.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Spanish Prime Minister Pédro Sanchez and European Commission President Ursula von der Leyen (AP Photo/Geert Vanden Wijngaert)

EU to launch vac­cine de­vel­op­ment and man­u­fac­tur­ing part­ner­ship with Latin Amer­i­can and Caribbean coun­tries

While European companies, including BioNTech, are focused on increasing vaccine access to African countries by setting up vaccine manufacturing facilities, the European Union is looking westward to Latin America and the Caribbean.

Speaking at a press conference with Spanish Prime Minister Pédro Sanchez, EU Commission president Ursula von der Leyen said that the EU is launching a new initiative for vaccines and medicines manufacturing in Latin America, to get drugs to Latin America and the Caribbean faster.

DEM BioPharma CEO David Donabedian (L) and executive chair Jan Skvarka

Long­wood sets an­oth­er 'don't eat me' biotech in­to gear with help of for­mer Tril­li­um CEO Jan Skvar­ka

Jonathan Weissman and team are out with a cancer-fighting biotech riding the appetite for those so-called “don’t eat me” and “eat me” signals.

The scientific co-founder — alongside fellow Whitehead Institute colleague Kipp Weiskopf and Stanford biologist Michael Bassik — has launched DEM BioPharma with incubator Longwood Fund and a crop of other investors.

In all, the nascent, 10-employee biotech has $70 million to bankroll hematology- and solid tumor-based programs, including a lead asset that could enter human trials in two to three years, CEO David Donabedian told Endpoints News.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.

Joe Wiley, Amryt Pharma CEO

Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The story of Amryt Pharma’s candidate for the genetic skin condition epidermolysis bullosa, or EB, will soon enter another chapter.

After the Irish drugmaker’s candidate, dubbed Oleogel-S10 and marketed as Filsuvez, was handed a CRL earlier this year, the company announced in a press release that it plans to submit a formal dispute resolution request for the company’s NDA for Oleogel-S10.

Kelly Martin, Radius Health CEO

VC firms take os­teo­poro­sis drug­mak­er Ra­dius Health pri­vate for al­most $900M

After attacks from activist investors and disappointing returns on share prices, Radius Health has now agreed to new ownership, a direction resulting in leaving the Nasdaq.

Radius Health, a biotech out of Massachusetts with one approved product in its arsenal, announced Thursday morning that it agreed to be acquired by two VC firms: Gurnet Point Capital and Patient Square Capital. The deal, worth around $890 million, will include debt assumption and the payout of $1 CVR per share for investors. And on top of that, OrbiMed is providing debt financing.